Description

Icatibant (HOE-140) is a potent and specific peptide antagonist of bradykinin B2 receptor with IC50 and Ki of 1.07 nM and 0.798 nM respectively[1][2][3].–20°C, 3 years (Powder)—-C59H89N19O13S—Biochem Biophys Res Commun. 2016 Apr 29;473(2):396-402. |Biomed Pharmacother. 2024 Mar 20:174:116489.|iScience. 2023 Jun 28.|J Renin Angiotensin Aldosterone Syst. 14 Jun 2022.|Nat Commun. 2023 May 2;14(1):2523.|Sci Rep. 2020 Aug 25;10(1):14160.|SSRN. 2023 Dec 27.|Adv Sci (Weinh). 2022 Oct 18;e2203088.-[1]Hock FJ, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol. 1991 Mar;102(3):769-73.|[2]Y Arai, et al. Effect of Icatibant, a Bradykinin B2 Receptor Antagonist, on the Development of Experimental Ulcerative Colitis in Mice. Dig Dis Sci. 1999 Apr;44(4):845-51.|[3]Marie-Thérèse Bawolak, et al The Bradykinin B2 Receptor Antagonist Icatibant (Hoe 140) Blocks Aminopeptidase N at Micromolar Concentrations: Off-Target Alterations of Signaling Mediated by the Bradykinin B1 and Angiotensin Receptors. Eur J Pharmacol. 2006 Dec 3;551(1-3):108-11.–130308-48-4–1304.52–99.51–[H][C@]1(C[C@@H](C(N[C@H](C(O)=O)CCCNC(N)=N)=O)N2C([C@@H]3N(C([C@H](CO)NC([C@H](CC4=CC=CS4)NC(CNC([C@@H]5C[C@@H](O)CN5C([C@H]6N(C([C@H](CCCNC(N)=N)NC([C@H](N)CCCNC(N)=N)=O)=O)CCC6)=O)=O)=O)=O)=O)CC7=C(C=CC=C7)C3)=O)[C@]2([H])CCCC1–Endocrinology–H2O : 100 mg/mL (ultrasonic)–Bradykinin Receptor–Bradykinin B2 Receptor (B2R)–GPCR/G Protein–Peptides